Cantor Fitzgerald Predicts ACRS FY2025 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Aclaris Therapeutics in a note issued to investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Agrawal forecasts that the biotechnology company will post earnings of ($0.54) per share for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share.

Several other equities research analysts have also recently weighed in on the company. Piper Sandler raised Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the company from $3.00 to $13.00 in a research note on Monday, November 18th. Leerink Partnrs upgraded shares of Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 19th. HC Wainwright upgraded Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Monday, December 23rd. Jefferies Financial Group raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and raised their price objective for the company from $2.00 to $7.00 in a research note on Tuesday, November 19th. Finally, BTIG Research raised Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price target for the company in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $11.00.

Aclaris Therapeutics Price Performance

Shares of Aclaris Therapeutics stock opened at $1.82 on Thursday. The firm has a market capitalization of $130.00 million, a P/E ratio of -3.50 and a beta of 0.50. Aclaris Therapeutics has a fifty-two week low of $0.95 and a fifty-two week high of $5.17. The company’s 50 day moving average price is $2.36 and its two-hundred day moving average price is $2.17.

Hedge Funds Weigh In On Aclaris Therapeutics

Institutional investors have recently bought and sold shares of the business. BML Capital Management LLC grew its stake in Aclaris Therapeutics by 9.7% during the 3rd quarter. BML Capital Management LLC now owns 14,250,000 shares of the biotechnology company’s stock worth $16,388,000 after buying an additional 1,261,866 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Aclaris Therapeutics by 187.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company’s stock valued at $382,000 after acquiring an additional 216,826 shares in the last quarter. Stonepine Capital Management LLC raised its position in shares of Aclaris Therapeutics by 27.6% in the 3rd quarter. Stonepine Capital Management LLC now owns 2,458,873 shares of the biotechnology company’s stock valued at $2,828,000 after purchasing an additional 531,427 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Aclaris Therapeutics in the 3rd quarter worth approximately $1,053,000. Finally, Geode Capital Management LLC increased its stake in Aclaris Therapeutics by 9.3% during the 3rd quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company’s stock valued at $974,000 after purchasing an additional 72,309 shares in the last quarter. 98.34% of the stock is owned by hedge funds and other institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.